The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.
Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis
Abstract
Background Azelastine hydrochloride is an antihistamine with anti-inflammatory properties that is available in the United States in a nasal spray formulation for the treatment of seasonal allergic rhinitis. Vasomotor (perennial nonallergic) rhinitis (VMR) is a noninfectious, chronic rhinitis usually not associated with inflammatory cell infiltration.Objective Two multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials were conducted to determine whether patients with symptoms of VMR (rhinorrhea, sneezing, postnasal drip, and nasal congestion) could be effectively treated with azelastine nasal spray.Methods All of the patients who participated in the trials had a diagnosis of VMR, symptoms for at least 1 year, negative skin tests for a mixed panel of seasonal and perennial allergens, and a nasal cytology examination negative for eosinophils. After a 1-week, single-blind, placebo lead-in period, patients who met the symptom severity qualification criteria were randomized to receive either azelastine nasal spray (two sprays per nostril twice daily, 1.1 mg/day) or placebo nasal spray for 21 days. Patients recorded the severity of their VMR symptoms on diary cards each morning and evening of the trial using a four-point symptom rating scale (0 = none to 3 = severe). The primary efficacy variable was the overall reduction from baseline in the total vasomotor rhinitis symptom score (TVRSS) over the 21-day, double-blind treatment period.Results In both studies, azelastine nasal spray significantly (study 1, P = .002; study 2, P = .005) reduced the TVRSS from baseline when compared with placebo. Significant improvement was observed within the first week and improvement in all symptoms favored treatment with azelastine nasal spray. No serious or unexpected adverse events were reported in either study. Bitter taste (19% vs 2%) was the only adverse experience that occurred with a statistically significantly greater incidence in the azelastine group than in the placebo group.Conclusions This is the first demonstration of the efficacy of an antihistamine in the therapy of VMR in two double-blind, placebo-controlled clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In clinical trials, azelastine has been shown to reduce symptoms of rhinitis, including postnasal drainage, sneezing, rhinorrhea, and congestion.188”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [188]
Citations
Cites
Allergy: Principles and Practice.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-817_10 · Cited by 1,696
Dykewicz, M. S., Fineman, S., Skoner, D. P., Nicklas, R., Lee, R., Blessing-Moore, J., Li, J. T., Bernstein, I. L., Berger, W., Spector, S., et al. (1998) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)63155-9 · Cited by 652
Allergy: Principles and Practice
Sheffer, A. L. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.281.20.1955 · Cited by 475
Mosimann, B. L., White, M. V., Hohman, R. J., Goldrich, M. S., Kaulbach, H. C., & Kaliner, M. A. (1993) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(93)90043-f · Cited by 190
Substance P and Neurokinin A in Human Nasal Mucosa
Baraniuk, J. N., Lundgren, J. D., Okayama, M., Goff, J., Mullol, J., Merida, M., Shelhamer, J. H., & Kaliner, M. A. (1991) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb/4.3.228 · Cited by 163
Molecular mechanisms of steroid action in asthma
Barnes, P. J. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)80216-8 · Cited by 113
Ciprandi, G., Pronzato, C., Passalacqua, G., Ricca, V., Grogen, J., Mela, G. S., VARESE, P., Bertolini, C., Bagnasco, M., & Canonica, G. W. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)80196-5 · Cited by 107
Yoneda, K., Yamamoto, T., Ueta, E., & Osaki, T. (1997) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.73.145 · Cited by 103
Hide, I., Toriu, N., Nuibe, T., Inoue, A., Hide, M., YAMAMOTO, S., & Nakata, Y. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.6.2932 · Cited by 102
Allergic and Non-Allergic Rhinitis: Clinical Aspects
Mygind, N., & Naclerio, R. M. (1993) · Medical Entomology and Zoology · Cited by 98
Research works printed but not linked: 4
- Economides, 1999, Vasomotor rhinitis: making the diagnosis and determining therapy, J Respir Dis, 20, 463
- Baumgarten, 1994, Modification of allergen-induced symptoms and mediator release by intranasal azelastine, J Pharmacol U Ther, 3, 43
- Pearlman, 1999, Azelastine nasal spray and skin test reactivity to histamine in rhinitis patients, Ann Allergy Asthma Immunol, 82, 89
- Matsumura, 1990, Inhibitory effects of azelastine on leukotriene B4, C4, and D4 release and production by bronchial asthmatic eosinophils, Respir Res, 9, 206
Cited by
Allergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis
Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Rhinitis 2020: A practice parameter update
Dykewicz, M. S., Wallace, D. V., Amrol, D. J., Baroody, F. M., Bernstein, J. A., Craig, T. J., Dinakar, C., Ellis, A. K., Finegold, I., Golden, D. B. K., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.007 · Cited by 436
Self-citationPaediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology
Roberts, G., Xatzipsalti, M., Borrego, L. M., Custovic, A., Halken, S., Hellings, P. W., Papadopoulos, N. G., Rotiroti, G., Scadding, G., Timmermans, F., et al. (2013) · Allergy · doi:10.1111/all.12235 · Cited by 416
Metadata
- Authors
- Banov, C. H., & Lieberman, P.
- Corresponding author
- Banov, Charles H.
- ORCID
- Lieberman, Phil
- Venue
- Annals of Allergy, Asthma & Immunology
- Publisher
- Elsevier BV
- Published
- 2001-01
- Volume
- 86
- Issue
- 1
- Pages
- 28-35
- ISSN
- 1081-1206 (ISSN-L)
- OpenAlex
- W2023228660
- Cited by
- 135
- References
- 40
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 8 · 2022: 1 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 7 · 2017: 7 · 2016: 7 · 2015: 9 · 2014: 6 · 2013: 3 · 2012: 4
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Annals of Allergy Asthma & Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Health Sciences › Medicine › Otorhinolaryngology › Sinusitis and nasal conditions
- Health Sciences › Medicine › Surgery › Nasal Surgery and Airway Studies
- Keywords
- azelastine, nasal spray, vasomotor rhinitis, antihistamines, anti-inflammatory agents, rhinitis symptom scores
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Aged, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Phthalazines, Placebos, Rhinitis, Vasomotor, Therapeutic Equivalency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. https://app.cochat.ai/papers/10.1016/s1081-1206(10)62352-6
- The paper
- Banov, C. H., & Lieberman, P. (2001). Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Annals of Allergy, Asthma & Immunology. https://doi.org/10.1016/s1081-1206(10)62352-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.